Form 4: Vicki Sato Sells VIR Biotechnology Shares

Vicki Sato, a Director at Vir Biotechnology, Inc., reported the sale of 22,000 shares of common stock for approximately $220,948 under a pre-arranged 10b5-1 trading plan.

Summary

• Vicki Sato, a Director at Vir Biotechnology, Inc. (VIR), has reported a transaction involving the sale of common stock.
• The sale consisted of 22,000 shares of common stock.
• The transaction occurred on May 1, 2026.
• The sale was executed under a Rule 10b5-1 trading plan adopted on March 27, 2025.
• The reported sale price was a weighted average of $10.0466 per share, with individual transactions ranging from $9.94 to $10.23.
• Following the sale, Vicki Sato beneficially owns 1,078,391 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves a director selling shares, the sale was conducted under a pre-established 10b5-1 plan, indicating it was likely pre-scheduled and not necessarily a reflection of negative sentiment towards the company.

Negatives

• Director Vicki Sato sold a significant number of shares (22,000) of company stock.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a past transaction.

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under Rule 10b5-1 plans, are common and often reflect pre-planned diversification or liquidity strategies rather than a negative view of the company's prospects. However, significant sales by directors can sometimes be interpreted by the market as a signal, depending on the volume and context.

Stakeholder Impact

• Shareholders may note the sale by a director, but the pre-planned nature of the transaction under a 10b5-1 plan suggests it is unlikely to be a reaction to new material non-public information.

Key Dates

Keywords

Form 4, Insider Trading, Stock Sale, Vir Biotechnology, Vicki Sato, Rule 10b5-1, Beneficial Ownership